((6R,9as)-八氢-1H-吡啶并[1,2-a]吡嗪-6-基)甲醇 | 816429-60-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌嗪基哌啶类
• 中文名称: ((6R,9as)-八氢-1H-吡啶并[1,2-a]吡嗪-6-基)甲醇
• 英文名称: cis-(octahydropyrido[1,2-a]pyrazin-6-yl)methanol
• 英文别名: (+/-)-(6R,9aS)-octahydro-2H-pyrido[1,2-a]pyrazin-6-ylmethanol；((6R,9AS)-Octahydro-1H-pyrido[1,2-A]pyrazin-6-YL)methanol；[(6R,9aS)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-6-yl]methanol
• CAS: 816429-60-4
• 化学式: C₉H₁₈N₂O
• 分子量: 170.255
• InChiKey: ITBZIIRMASQCRM-DTWKUNHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ((6R,9as)-八氢-1H-吡啶并[1,2-a]吡嗪-6-基)甲醇 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 (6RS,9aRS)-2-furan-2-yl-5-[6-(1H-indol-5-yloxymethyl)octahydropyrido[1,2-a]pyrazin-2-yl][1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ylamine
  参考文献：
  名称：

  Novel Bicyclic Piperazine Derivatives of Triazolotriazine and Triazolopyrimidines as Highly Potent and Selective Adenosine A_2A Receptor Antagonists

  摘要：

  A series of bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines was synthesized. Some of these analogues show high affinity and excellent selectivity for adenosine A(2a) receptor versus the adenosine A(1) receptor. Structure-activity-relationship (SAR) studies based on octahydropyrrolo[1,2-a]pyrazine and octahydropyrido[1,2-a]pyrazine with various capping groups are reported. Among these analogues, the most potent and selective A(2a) antagonist 26h has a K-i value of 0.2 nM and is 16500-fold selective with respect to the A(1) receptor. Among a number of compounds tested, compounds 21a and 21c exhibited significantly improved metabolic stability. Compounds 21a, 21c, and 18a showed good oral efficacy in rodent catalepsy models of Parkinson's disease.

  DOI：

  10.1021/jm0494321
• 作为产物：
  描述：

  (+/-)-methyl (6R,9aS)-1,4-dioxooctahydro-2H-pyrido[1,2-a]pyrazine-6-carboxylate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以100%的产率得到((6R,9as)-八氢-1H-吡啶并[1,2-a]吡嗪-6-基)甲醇
  参考文献：
  名称：

  Bicyclic piperazines as metabotropic glutatmate receptor antagonists

  摘要：

  该发明涉及公式I的化合物或其药用可接受的盐或溶剂化合物：其中Ar1、A、Hy、R1、m和n如描述中所定义。该发明还包括药物组合物、使用方法以及制备这些化合物的方法，以及治疗mGluR5介导的疾病的医疗方法。

  公开号：

  US20070037816A1

文献信息

• Acetylenic piperazines as metabotropic glutamate receptor antagonists
  申请人：Edwards Louise

  公开号：US20070037817A1

  公开（公告）日：2007-02-15

  The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar 1 , A, B, R 1 , m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR 5 mediated disorders.

  该发明涉及公式I的化合物或其药用可接受的盐或溶剂，其中Ar1、A、B、R1、m和n如描述中所定义。该发明还包括药物组合物和用途，以及制备这些化合物的方法，以及治疗mGluR 5介导的疾病的医疗方法。
• Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists
  申请人：Edwards Louise

  公开号：US20080194571A1

  公开（公告）日：2008-08-14

  The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar 1 , A, B, R 1 , m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR 5 mediated disorders.

  本发明涉及公式I化合物或其药学上可接受的盐或溶剂：其中Ar1，A，B，R1，m和n如描述中所定义。本发明还包括药物组合物和使用以及制备该化合物的方法，以及治疗mGluR5介导的疾病的医疗方法。
• Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists
  申请人：Edwards Louise

  公开号：US20080312240A1

  公开（公告）日：2008-12-18

  The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar 1 , A, Hy, R 1 , m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR5-mediated disorders.

  本发明涉及化合物I的公式或其药学上可接受的盐或溶剂：其中Ar1、A、Hy、R1、m和n如说明书所定义。本发明还包括制备该化合物的制剂、用途和方法，以及治疗mGluR5介导的疾病的医疗方法。
• BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：AstraZeneca AB

  公开号：EP1919911A1

  公开（公告）日：2008-05-14
• ACETYLENIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：AstraZeneca AB

  公开号：EP1919915A2

  公开（公告）日：2008-05-14